应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
IND Xtrackers Nifty 500 India ETF
休市中 12-05 16:00:00 EST
24.80
+0.02
+0.06%
最高
24.83
最低
24.80
成交量
296.00
今开
24.83
昨收
24.79
日振幅
0.12%
总市值
496.00万
流通市值
496.00万
总股本
20.00万
成交额
7,349
换手率
0.15%
流通股本
20.00万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
港股异动 | 百奥赛图-B(02315)涨超3% 授权IDEAYA双抗ADC项目IDE034获FDA IND批准
智通财经 · 12-05 14:46
港股异动 | 百奥赛图-B(02315)涨超3% 授权IDEAYA双抗ADC项目IDE034获FDA IND批准
百奥赛图-B(02315)业务合作伙伴IDEAYA取得美国食品药品监督管理局对IDE034的IND批准
智通财经 · 12-05 08:09
百奥赛图-B(02315)业务合作伙伴IDEAYA取得美国食品药品监督管理局对IDE034的IND批准
德琪医药-B(06996):ATG-022联合KEYTRUDA®(帕博利珠单抗)±化疗的IB/II期研究于中国获授予IND批准
智通财经 · 12-02
德琪医药-B(06996):ATG-022联合KEYTRUDA®(帕博利珠单抗)±化疗的IB/II期研究于中国获授予IND批准
和誉-B(02256):口服小分子KRAS G12D抑制剂 ABSK141的IND申请获FDA批准
智通财经 · 12-01
和誉-B(02256):口服小分子KRAS G12D抑制剂 ABSK141的IND申请获FDA批准
维立志博-B(09887):LBL-047取得NMPA的IND批准
智通财经 · 12-01
维立志博-B(09887):LBL-047取得NMPA的IND批准
暂无数据
公司概况
公司名称:
Xtrackers Nifty 500 India ETF
所属市场:
NASDAQ
上市日期:
--
主营业务:
荷兰国际集团是在1991年由荷兰国民人寿保险公司和荷兰邮政银行集团合并组成的综合性财政金融集团。据美国财富(FORTUNES)杂志统计,以资产净值计算,荷兰国际集团位居全球500家大企业的第64位。在提供综合性金融财经业务方面(银行与保险业务),居世界第三位。目前,该集团在世界上65个国家和地区设有分支机构,雇员超过10万人。2000年,该集团取得税后净利润49亿欧元,同比增长24%。截至2000年底,集团资产总额达5030亿欧元。 管理结构: 在董事会下面设有四个管理运作核心,荷兰总部;国际金融财经业务部;企业和资本市场部;资产管理部。 集团总部:负责荷兰本国市场上的全部保险和银行业务。 国际金融财经业务部:所有荷兰本土以外的国际保险业、零售银行业和商业银行业的运作皆由该中心管理。其保险业务划分三大地区:欧洲和拉丁美洲、北美洲、亚澳地区。银行业务则由中心统一管理。 企业及资本市场部:所有国际货币和资本市场管理部门都由该部门管理。包括国际银行网络以及金融产品、贸易、销售、投资银行、企业银行、风险管理及调研的各项业务。 资产管理部:该部门承担企业投资者的资产和帐目管理、提供个人国际银行服务以及集团公司的保险业务的资产管理。房地产业务和信托业务也属于这个部门管理。该部门同时管理荷兰国际集团各个公司的投资基金。
发行价格:
--
{"stockData":{"symbol":"IND","market":"US","secType":"STK","nameCN":"Xtrackers Nifty 500 India ETF","latestPrice":24.8,"timestamp":1764968400000,"preClose":24.785,"halted":0,"volume":296,"delay":0,"floatShares":200001,"shares":200001,"eps":0,"marketStatus":"休市中","change":0.015,"latestTime":"12-05 16:00:00 EST","open":24.83,"high":24.83,"low":24.8,"amount":7348.998608,"amplitude":0.00121,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":24.785,"sharesOutstanding":200001,"nav":24.816,"aum":4963216.28,"bidAskSpread":0,"volumeRatio":0.5138889156539366},"requestUrl":"/m/hq/s/IND/tweets","defaultTab":"tweets","newsList":[{"id":"2589448869","title":"港股异动 | 百奥赛图-B(02315)涨超3% 授权IDEAYA双抗ADC项目IDE034获FDA IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589448869","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589448869?lang=zh_cn&edition=full","pubTime":"2025-12-05 14:46","pubTimestamp":1764917191,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B涨超3%,截至发稿,涨2.84%,报31.86港元,成交1299.1万港元。IDEAYA预计将在2026年第一季度开始患者入组,初步评估B7H3和PTK7共表达的实体瘤类型,包括肺癌、结直肠癌、头颈癌及卵巢/妇科肿瘤。此外,IDEAYA计划探索IDE034与其PARG抑制剂IDE161的联合治疗策略,以增强疗效持续性,并计划在2026年上半年重要医学会议上分享更多支持PARG与TOP1 ADC联合治疗机制的数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","688796","BK4231","ADC","BK4080","02315","BK1161"],"gpt_icon":0},{"id":"2589855702","title":"百奥赛图-B(02315)业务合作伙伴IDEAYA取得美国食品药品监督管理局对IDE034的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2589855702","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589855702?lang=zh_cn&edition=full","pubTime":"2025-12-05 08:09","pubTimestamp":1764893379,"startTime":"0","endTime":"0","summary":"IDEAYA预计将在2026年第一季度开始患者入组,初步评估B7H3和PTK7共表达的实体瘤类型,包括肺癌、结直肠癌、头颈癌及卵巢╱ 妇科肿瘤。B7H3和PTK7在肺癌、结直肠癌及头颈癌等实体瘤中的共表达比例分别约为30%、46% 和27%,显示IDE034广泛的临床适应症潜力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377962.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IND","02315","688796"],"gpt_icon":1},{"id":"2588035332","title":"德琪医药-B(06996):ATG-022联合KEYTRUDA®(帕博利珠单抗)±化疗的IB/II期研究于中国获授予IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588035332","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588035332?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:45","pubTimestamp":1764665132,"startTime":"0","endTime":"0","summary":"智通财经APP讯,德琪医药-B(06996)发布公告,中国国家药品监督管理局(国家药监局)已批准用于评估 ATG-022(CLDN18.2抗体药物偶联物ADC)联 合 MSD (Merck & Co., Inc., Rahway, NJ, USA)的抗PD 1疗法KEYTRUDA®(帕博利珠单抗)以及ATG-022联合帕博利珠单抗及化疗的Ib/II期CLINCH-2研究的研究性新药(IND)申请。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","IND","BK1583","06996"],"gpt_icon":0},{"id":"2588210723","title":"和誉-B(02256):口服小分子KRAS G12D抑制剂 ABSK141的IND申请获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588210723","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588210723?lang=zh_cn&edition=full","pubTime":"2025-12-01 17:40","pubTimestamp":1764582054,"startTime":"0","endTime":"0","summary":"智通财经APP讯,和誉-B(02256)发布公告,公司的附属公司上海和誉生物医药科技有限公司宣布,一种用于治疗携带KRAS G12D突变的晚期实体瘤患者的口服、高活性、高选择性小分子KRAS G12D抑制剂ABSK141的新药临床试验(IND)申请已获得美国食品药品监督管理局(FDA)批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1376033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","02256","BK1161","IE00B543WZ88.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU2476274308.USD","LU2778985437.USD","LU2476274720.SGD","IND"],"gpt_icon":0},{"id":"2588382740","title":"维立志博-B(09887):LBL-047取得NMPA的IND批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2588382740","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588382740?lang=zh_cn&edition=full","pubTime":"2025-12-01 16:32","pubTimestamp":1764577967,"startTime":"0","endTime":"0","summary":"智通财经APP讯,维立志博-B 发布公告,于2025年11月25日,其自主研发候选药物LBL-047的新药临床试验申请已获中国国家药品监督管理局批准。目前全球范围内尚无同时靶向浆细胞样树突状细胞及B细胞的药物获批临床试验。LBL-047凭借此独特作用机制,具备同类第一及同类最优的潜力。其将评估LBL-047的安全性、耐受性及其在SLE患者中的初步临床有效性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09887","HK0000252160.HKD","BK1161","IND","HK0000252152.HKD","HK0000500386.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ing.com","stockEarnings":[{"period":"1week","weight":-0.0177},{"period":"1month","weight":-0.0082},{"period":"ytd","weight":-0.0082}],"compareEarnings":[{"period":"1week","weight":0.0034},{"period":"1month","weight":0.012},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1445},{"period":"1year","weight":0.1303},{"period":"ytd","weight":0.17}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"荷兰国际集团是在1991年由荷兰国民人寿保险公司和荷兰邮政银行集团合并组成的综合性财政金融集团。据美国财富(FORTUNES)杂志统计,以资产净值计算,荷兰国际集团位居全球500家大企业的第64位。在提供综合性金融财经业务方面(银行与保险业务),居世界第三位。目前,该集团在世界上65个国家和地区设有分支机构,雇员超过10万人。2000年,该集团取得税后净利润49亿欧元,同比增长24%。截至2000年底,集团资产总额达5030亿欧元。 管理结构: 在董事会下面设有四个管理运作核心,荷兰总部;国际金融财经业务部;企业和资本市场部;资产管理部。 集团总部:负责荷兰本国市场上的全部保险和银行业务。 国际金融财经业务部:所有荷兰本土以外的国际保险业、零售银行业和商业银行业的运作皆由该中心管理。其保险业务划分三大地区:欧洲和拉丁美洲、北美洲、亚澳地区。银行业务则由中心统一管理。 企业及资本市场部:所有国际货币和资本市场管理部门都由该部门管理。包括国际银行网络以及金融产品、贸易、销售、投资银行、企业银行、风险管理及调研的各项业务。 资产管理部:该部门承担企业投资者的资产和帐目管理、提供个人国际银行服务以及集团公司的保险业务的资产管理。房地产业务和信托业务也属于这个部门管理。该部门同时管理荷兰国际集团各个公司的投资基金。","yearOnYearQuotes":[{"month":1,"riseRate":0.857143,"avgChangeRate":0.027152},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.031592},{"month":3,"riseRate":0.785714,"avgChangeRate":0.035422},{"month":4,"riseRate":0.571429,"avgChangeRate":0.017359},{"month":5,"riseRate":0.285714,"avgChangeRate":0.00595},{"month":6,"riseRate":0.714286,"avgChangeRate":0.006634},{"month":7,"riseRate":0.785714,"avgChangeRate":0.023298},{"month":8,"riseRate":0.4,"avgChangeRate":-0.016348},{"month":9,"riseRate":0.571429,"avgChangeRate":-0.024108},{"month":10,"riseRate":0.785714,"avgChangeRate":0.022259},{"month":11,"riseRate":0.357143,"avgChangeRate":-0.033495},{"month":12,"riseRate":0.642857,"avgChangeRate":0.020836}],"exchange":"NASDAQ","name":"Xtrackers Nifty 500 India ETF","nameEN":"Xtrackers Nifty 500 India ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xtrackers Nifty 500 India ETF(IND)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Xtrackers Nifty 500 India ETF(IND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Xtrackers Nifty 500 India ETF,IND,Xtrackers Nifty 500 India ETF股票,Xtrackers Nifty 500 India ETF股票老虎,Xtrackers Nifty 500 India ETF股票老虎国际,Xtrackers Nifty 500 India ETF行情,Xtrackers Nifty 500 India ETF股票行情,Xtrackers Nifty 500 India ETF股价,Xtrackers Nifty 500 India ETF股市,Xtrackers Nifty 500 India ETF股票价格,Xtrackers Nifty 500 India ETF股票交易,Xtrackers Nifty 500 India ETF股票购买,Xtrackers Nifty 500 India ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xtrackers Nifty 500 India ETF(IND)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Xtrackers Nifty 500 India ETF(IND)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}